Marta Mascarenas-Garcia

Marta Mascarenas-Garcia

Auto-generated profile, based on publicly available information

Marta Mascarenas-Garcia

Department of Preventive Medicine and Public Health Universidade de Santiago de Compostela. Rúa San Francisco s/n Santiago de Compostela Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2026 in Annals of Neurology
Verified
Journal Article
Open access
MMMarta Mascareñas‐García
Marta Mascareñas‐García
ARAlejandro Rivero‐De‐Aguilar
Alejandro Rivero‐De‐Aguilar
CCCristina Candal‐Pedreira
Cristina Candal‐Pedreira
GGGuadalupe García
Guadalupe García
CTCarla Guerra Tort
Carla Guerra Tort
Maria Leonor Varela LemaMaria Leonor Varela Lema
Maria Leonor Varela Lema
Objective: Spin refers to reporting strategies that highlight the benefits of an experimental treatment or divert attention from nonsignificant primary outcomes. We aimed to assess spin in randomized controlled trials (RCTs) on pharmaceutical efficacy in multiple sclerosis (MS) and explore associated factors. Methods: A systematic literature search was conducted in MedLine (PubMed), EMBASE, and Cochrane using database‐specific thesauri (“Multiple Sclerosis” and “Drug Therapy”) to identify relevant studies. We included multiple sclerosis phase 3 and 4 randomized controlled trials with parallel, superiority designs that were published between 2013 and 2024 reporting nonsignificant primary outcomes. Spin was assessed in title, abstract conclusion, results, discussion, and conclusions. A descriptive analysis was followed by exploratory bivariate logistic regression. Independent variables included trial phase, sample size, drug type, comparison, follow‐up time, registration, Consolidated Standards of Reporting Trials (CONSORT) mention, risk of bias (RoB2), journal quartile, first author affiliation, and conflict of interest. Results: Forty articles met inclusion criteria. Spin appeared in at least one section in 25 articles (62.5%) and in 3 or more in 19 articles (47.5%). The most frequent locations were abstract conclusions, discussion, and conclusions. Spin was significantly associated with smaller sample size (odds ratio [OR] = 7.00, 95% confidence interval [CI] = 1.29–37.91, p = 0.024), non‐Q1 journals (OR = 4.38, 95% CI = 1.03–18.63, p = 0.046), and first author affiliation outside Europe or the United States (OR = 5.09, 95% CI = 1.15–22.62, p = 0.032). Interpretation: Spin is common in MS randomized controlled trials with nonsignificant primary outcomes and may mislead clinical decisions. ANN NEUROL 2026;99:316–327

4 August 2023 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
MMMarta Mascarenas-Garcia
Marta Mascarenas-Garcia
ARAlejandro Rivero-De-Aguilar
Alejandro Rivero-De-Aguilar
MPMonica Pérez-Ríos
Monica Pérez-Ríos
ARAlberto Ruano-Raviña
Alberto Ruano-Raviña
MLMiguel Angel Llaneza-Gonzalez
Miguel Angel Llaneza-Gonzalez
LVLeonor Varela-Lema
Leonor Varela-Lema
Background Great advances have been made in the field of multiple sclerosis (MS) therapy due to the publication of numerous randomised clinical trials (RCTs). In this study, we carried out a critical appraisal of phase III RCTs of disease-modifying therapies (DMTs) for MS published after 2010, intending to identify critical areas of improvement. Methods We performed a systematic search of published RCTs on MS from January 2010 until December 2021. RCTs were assessed using an ad-hoc tool. This tool was developed based on existing generic methodological instruments and MS-specific guidelines and methodological papers. It included 14 items grouped in 5 domains: methodological quality, adequacy and measurement of outcomes, adverse event reporting, applicability and relevance of results, and transparency and conflict of interest. Results We identified 31 phase III RCTs. Most of them were fully compliant in terms of sample size (87%), randomisation (68%), blinding (61%), participant selection (68%), adverse event reporting (84%) and clinical relevance (52%). Only a few were compliant in terms of participant description (6%), comparison (42%), attrition bias (26%), adequacy of outcome measures (26%), applicability (23%), transparency (36%) and conflict of interest (6%). None were compliant in terms of analysis and reporting of outcomes. The most common limitations related to the absence of comorbidity data, unjustified use of placebo, inadequacy of outcomes design and absence of protocol and/or prospective registration. Conclusions RCTs for DMTs in MS have relevant and frequent limitations. These should be addressed to enhance their quality, transparency and external validity.